UK markets closed

Immunicum AB (publ) (IMMU.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
3.7600-0.0400 (-1.05%)
At close: 5:29PM CEST
Full screen
Previous close3.8000
Open3.8000
Bid3.7200 x 0
Ask3.7550 x 0
Day's range3.6600 - 4.0000
52-week range3.6100 - 9.7550
Volume77,509
Avg. volume303,351
Market cap749.748M
Beta (5Y monthly)1.00
PE ratio (TTM)N/A
EPS (TTM)-1.1220
Earnings date28 Oct 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.70
  • Globe Newswire

    Immunicum Appoints New Experts in Cancer Immunology to Scientific Advisory Board

    Press Release 30 September 2021 Immunicum Appoints New Experts in Cancer Immunology to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) today announced the appointment of Ada M. Kruisbeek, PhD, Sjoerd H. van der Burg, PhD, and Tanja D. de Gruijl, PhD, to its Scientific Advisory Board (SAB). These leading experts in cancer immunology were previously members of the SAB of DCprime and will join existing Immunicum SAB members, Inge Marie Svane, MD, PhD, and Pawel Kalinski MD, PhD. Dr Kruisbeek

  • Globe Newswire

    Immunicum AB (publ) Announces Outcome of Subscription in Incentive Program LTI 2021/2024

    Press Release 29 September 2021 Immunicum AB (publ) Announces Outcome of Subscription in Incentive Program LTI 2021/2024 Immunicum AB (publ) announced today the outcome of the subscription of employee stock options and restricted share units in the incentive program LTI 2021/2024 resolved by the Annual General Meeting on 4 May 2021. In total, 1,286,092 employee stock options and 660,000 restricted share units have been subscribed, representing a dilution of 0.97 percent if all employee stock opt

  • Globe Newswire

    Immunicum and the University Medical Center Groningen Receive a Grant from Health~Holland to Broaden Cancer Relapse Vaccine Development for Ovarian Cancer

    Press Release 8 September 2021 Immunicum and the University Medical Center Groningen Receive a Grant from Health~Holland to Broaden Cancer Relapse Vaccine Development for Ovarian Cancer Immunicum AB (publ; IMMU.ST) announced today that it has initiated a new research collaboration with the University Medical Center Groningen (UMCG), to explore novel treatment options for ovarian cancer based on the combination of Immunicum’s cell-based cancer vaccine platform with immune checkpoint inhibitors (C